AVA 3996
Alternative Names: AVA-2727D; AVA-3996Latest Information Update: 11 Jan 2024
Price :
$50 *
At a glance
- Originator Avacta
- Class Antineoplastics; Drug conjugates
- Mechanism of Action Proteasome inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 11 Oct 2023 Pharmacodynamics data from preclinical studies in Solid tumours presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023
- 28 Sep 2023 Avacta plans to file CTA/IND for Solid tumours in second half of 2024
- 17 Apr 2023 Pharmacodynamics and adverse events data from preclinical trial in Solid tumours presented at the American Association for Cancer Research Annual Meeting (AACR-2023)